Becton, Dickinson and Company (NYSE:BDX) Shares Acquired by Studio Investment Management LLC

Studio Investment Management LLC lifted its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 2.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,614 shares of the medical instruments supplier’s stock after purchasing an additional 119 shares during the quarter. Studio Investment Management LLC’s holdings in Becton, Dickinson and Company were worth $1,354,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Livelsberger Financial Advisory acquired a new stake in shares of Becton, Dickinson and Company during the 3rd quarter worth approximately $26,000. Ashton Thomas Securities LLC acquired a new stake in shares of Becton, Dickinson and Company during the 3rd quarter worth approximately $33,000. Tompkins Financial Corp grew its stake in shares of Becton, Dickinson and Company by 44.2% during the 3rd quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock worth $36,000 after purchasing an additional 46 shares during the period. Sound Income Strategies LLC grew its stake in Becton, Dickinson and Company by 35.8% in the 3rd quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock valued at $40,000 after acquiring an additional 44 shares during the period. Finally, Kennebec Savings Bank acquired a new stake in Becton, Dickinson and Company in the 3rd quarter valued at $46,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Trading Up 1.3 %

Shares of BDX opened at $225.21 on Friday. Becton, Dickinson and Company has a 52-week low of $218.75 and a 52-week high of $249.89. The company has a quick ratio of 0.74, a current ratio of 1.17 and a debt-to-equity ratio of 0.69. The firm’s fifty day moving average is $235.35 and its two-hundred day moving average is $234.65. The stock has a market cap of $65.10 billion, a PE ratio of 37.91, a price-to-earnings-growth ratio of 1.66 and a beta of 0.43.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.77 by $0.04. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. The company had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. During the same quarter in the previous year, the company posted $3.42 EPS. The firm’s quarterly revenue was up 6.9% on a year-over-year basis. Research analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 31st. Stockholders of record on Monday, December 9th will be issued a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a dividend yield of 1.85%. The ex-dividend date of this dividend is Monday, December 9th. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. Becton, Dickinson and Company’s payout ratio is currently 63.97%.

Analyst Ratings Changes

A number of research firms recently issued reports on BDX. Raymond James dropped their price target on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research note on Friday, August 2nd. Citigroup raised shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and lifted their price target for the company from $255.00 to $275.00 in a research note on Tuesday, October 1st. Evercore ISI lifted their price target on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Finally, Stifel Nicolaus lifted their price target on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a research note on Friday, July 26th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $283.00.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.